ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
March 11, 2020Takeda Pharmaceutical announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients. -
Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike
February 24, 2019In Takeda’s last quarterly report as a separate company from Shire, things seem to be going its way—key drugs are growing nicely, Shire integration is on track, and cash-raising sell-offs are underway, executives said. -
Takeda's Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma
July 17, 2018After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib).
Pharma Sources Insight January 2025
